Xintela announces today that the company has signed a contract with GreenLight Clinical, an Australian Contract Research Organisation (CRO) to conduct Xintela’s First-in-Human study using the stem cell product XSTEM.
Xintela’s First-in-Human study with the stem cell product XSTEM, a combined phase I/II clinical study on patients with knee osteoarthritis, will be conducted in Australia and is planned to be initiated in Q4 2021. An agreement with the Contract Research Organisation (CRO) GreenLight Clinical (GLC), headquartered in Sydney, Australia, has now been signed. Xintela has collaborated with GLC since 2019, and this now continues with the full-service execution of the clinical study.
“We are very pleased to have selected GreenLight Clinical (GLC) as our partner in this First-In-Human study. We have for some time worked with GLC on regulatory matters and preparation of core clinical documents. We have established a productive working relationship and good foundation to continue our partnership as Xintela now enters clinical development of XSTEM. At the same time, Xintela is strengthening our clinical development team in-house, which is essential to successfully drive our clinical programs forward”, says Xintela’s CEO, Evy Lundgren-Åkerlund.
“We are delighted to partner with Xintela for the XSTEM-OA study, and further strengthen the close ties between our respective organizations. GreenLight and Xintela share a common goal of bringing new and innovative treatments to patients in need. With Australia’s renowned clinical research environment, GreenLight’s personal and customised approach will enable Xintela to rapidly advance the XSTEM program. We look forward to working closely once again with Xintela, and take this product into the clinic, and beyond”, says GreenLight Clinical’s CEO, Franz D´Lima.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se
About GreenLight Clinical
GreenLight Clinical is a full-service CRO specialised in early phase studies, based in Australia with operations across North America, Europe and Asia Pacific. For more information, please refer to www.greenlightclinical.com.
About Xintela
Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Chairman Gregory Batcheller visited BioStock’s studio to tell us more about the company’s journey and business development.
CEO Evy Lundgren-Åkerlund presents the company at BioStock Investor Meeting on March 16, 2023.
CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Fall Summit 2022 on November 30.
Targinta's CEO Per Norlén presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
CEO Evy Lundgren-Åkerlund presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Spring Summit 2022.
Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).
BioStock interview with Xintela's CMO and board member Sven Kili.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
